Contract Development and Manufacturing Organizations (CDMOs) Market, Share, Growth, and Industry Analysis by Type (API Development, Manufacturing, and Drug Delivery) by Application (Pharmaceutical Company, Biotechnology Company, and Generic Company) Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET OVERVIEW

In 2026, the global Contract Development and Manufacturing Organizations (CDMOs) Market is estimated at USD 140.3 Billion. With consistent expansion, the market is projected to attain USD 333.4 Billion by 2035. The market is forecast to grow at a CAGR of 10% over the period from 2026 to 2035.

The Contract Development and Manufacturing Organizations (CDMOs) market is expanding rapidly due to increasing outsourcing activities by pharmaceutical and biotechnology companies seeking cost-efficient drug development and manufacturing capabilities. Approximately 71% of pharmaceutical companies outsourced at least one manufacturing operation during 2025. Biologics manufacturing accounted for nearly 38% of CDMO service demand globally. Small molecule drug production represented around 44% of outsourcing contracts. Continuous manufacturing technologies increased by 23% across CDMO facilities during 2024. Sterile injectable manufacturing projects contributed approximately 31% of total outsourcing activity. Advanced drug delivery systems integrated within CDMO operations improved production efficiency by nearly 27% across large-scale pharmaceutical manufacturing facilities worldwide.

The United States accounted for approximately 41% of global CDMO market demand during 2025 because of strong pharmaceutical research infrastructure and increasing biologics production requirements. More than 63% of U.S.-based pharmaceutical companies outsourced clinical manufacturing and API production services. Cell and gene therapy outsourcing projects increased by 29% during 2024. Around 58% of biotechnology startups in the U.S. partnered with CDMOs for early-stage drug development support. Sterile injectable manufacturing capacity utilization exceeded 76% across major U.S. CDMO facilities. AI-enabled process optimization technologies improved manufacturing efficiency by approximately 24% in pharmaceutical production plants across the country.

KEY FINDINGS

LATEST TRENDS

Growing Innovation and Collaboration Among Market Players to Sustain Market Development

The Contract Development and Manufacturing Organizations (CDMOs) market is witnessing rapid transformation due to rising biologics demand, advanced drug delivery technologies, and increasing outsourcing of clinical manufacturing operations. Approximately 61% of pharmaceutical companies outsourced biologics production during 2025 because of rising manufacturing complexity and regulatory requirements. Continuous manufacturing systems increased by 24% across CDMO facilities to improve scalability and operational efficiency. Cell and gene therapy manufacturing projects expanded by nearly 31% globally during 2024. AI-enabled production monitoring systems improved batch consistency by approximately 22% in large pharmaceutical manufacturing plants. Sterile injectable manufacturing represented nearly 34% of total CDMO expansion projects due to increasing demand for oncology and specialty therapeutics. Single-use bioreactor installations increased by 27% because of reduced contamination risks and lower operational downtime.

Around 49% of CDMOs integrated cloud-connected manufacturing execution systems for real-time production monitoring and quality control. High-potency active pharmaceutical ingredient facilities also expanded by 19% globally during 2025. Personalized medicine manufacturing and small-batch production capabilities gained significant traction across CDMO networks worldwide. Approximately 38% of biotechnology companies prioritized flexible manufacturing partnerships for rapid clinical trial support. Automation-enabled packaging systems improved pharmaceutical packaging efficiency by nearly 18% across large-scale production facilities. Sustainable manufacturing technologies, including energy-efficient processing systems and waste reduction programs, increased by approximately 21% across global CDMO operations.

Download Free Sample to learn more about this report

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SEGMENTATION

By Type

According to type, the market can be segmented into API Development, Manufacturing, and Drug Delivery. The API development segment is projected to dominate the market share during 2022-2028.

• API Development: API development accounted for approximately 33% of the Contract Development and Manufacturing Organizations (CDMOs) market during 2025 due to rising pharmaceutical outsourcing and increasing demand for complex active pharmaceutical ingredients. Small molecule API manufacturing represented nearly 58% of total API outsourcing activity globally. High-potency API production facilities expanded by 22% during 2024 because of increasing oncology drug demand. Around 46% of pharmaceutical companies outsourced process optimization and analytical testing services. Continuous manufacturing technologies improved API production efficiency by approximately 19%. Biologics-related API development projects represented nearly 27% of new outsourcing contracts globally. AI-enabled process analytics also increased by 17% across advanced pharmaceutical manufacturing facilities.

• Manufacturing: Manufacturing services dominated the CDMO market with approximately 46% share during 2025 because of extensive outsourcing of commercial-scale drug production and packaging operations. Sterile injectable manufacturing represented nearly 34% of manufacturing demand globally. Around 61% of pharmaceutical companies outsourced oral solid dosage production during 2025. Single-use bioprocessing systems increased by 24% across biologics manufacturing facilities. Automated packaging technologies improved operational efficiency by approximately 18% in high-volume pharmaceutical production plants. Clinical trial manufacturing projects expanded by 21% due to increasing specialty drug development. Flexible manufacturing systems supporting small-batch personalized medicine production also increased by approximately 16% globally.

• Drug Delivery: Drug delivery services accounted for approximately 21% of the CDMO market because of increasing demand for advanced formulations and specialty therapeutic products. Injectable drug delivery systems represented nearly 39% of outsourced formulation projects during 2025. Liposomal and nanoparticle-based drug delivery technologies increased by 18% globally due to rising biologics commercialization. Around 42% of biotechnology companies outsourced formulation development and stability testing services. Controlled-release oral dosage systems accounted for approximately 24% of drug delivery outsourcing activity. Advanced inhalation drug delivery manufacturing projects also increased by 16% during 2024. AI-supported formulation optimization technologies improved development timelines by approximately 20% across pharmaceutical outsourcing operations.

By Application 

Based on application, the market can be divided into Pharmaceutical Company, Biotechnology Company, Generic Company. The pharmaceutical company segment is anticipated to hold the maximum market share through 2028.

• Pharmaceutical Company: Pharmaceutical companies dominated the Contract Development and Manufacturing Organizations (CDMOs) market with approximately 57% share during 2025 due to increasing outsourcing of commercial manufacturing, clinical trial support, and packaging operations. Around 69% of large pharmaceutical companies outsourced at least one biologics manufacturing process globally. Sterile injectable production represented nearly 33% of pharmaceutical outsourcing demand during 2025. Continuous manufacturing technologies improved operational efficiency by approximately 21% across outsourced production facilities. Clinical trial material outsourcing increased by 26% globally during 2024. Pharmaceutical innovators also expanded outsourcing partnerships for personalized medicine and specialty therapeutic manufacturing projects.

• Biotechnology Company: Biotechnology companies accounted for approximately 29% of CDMO market demand because of increasing biologics commercialization and limited in-house manufacturing capabilities. Monoclonal antibody manufacturing represented nearly 41% of biotechnology outsourcing projects globally during 2025. Around 58% of biotechnology startups relied on CDMOs for process development and regulatory support services. Cell and gene therapy outsourcing increased by 31% during 2024 due to growing advanced therapy clinical trials. Single-use bioreactor systems improved manufacturing flexibility by approximately 19% across biotechnology-focused CDMO facilities. AI-integrated production monitoring systems also increased by 17% within biologics outsourcing operations globally.

• Generic Company: Generic companies represented approximately 14% of the Contract Development and Manufacturing Organizations (CDMOs) market due to increasing outsourcing of cost-efficient drug production and packaging operations. Oral solid dosage manufacturing accounted for nearly 48% of generic outsourcing demand during 2025. Around 37% of generic drug manufacturers partnered with CDMOs for API synthesis and regulatory documentation support. Continuous production technologies improved manufacturing throughput by approximately 18% across generic pharmaceutical facilities. Packaging and serialization services represented nearly 26% of outsourcing activity globally. Emerging markets increased generic drug outsourcing projects by approximately 21% during 2024 because of expanding pharmaceutical access and healthcare infrastructure modernization.

MARKET DYNAMICS

Driving Factor

Increasing outsourcing by pharmaceutical and biotechnology companies.

The Contract Development and Manufacturing Organizations (CDMOs) market is strongly driven by increasing outsourcing strategies adopted by pharmaceutical and biotechnology companies to reduce operational costs and accelerate drug commercialization timelines. Approximately 74% of pharmaceutical companies outsourced at least one stage of manufacturing during 2025. Clinical trial material production outsourcing increased by 28% globally during 2024. Around 59% of biotechnology startups relied on CDMOs for biologics process development and commercial-scale manufacturing. Sterile injectable outsourcing projects represented nearly 31% of manufacturing demand globally. Advanced process automation technologies improved production efficiency by approximately 23% across outsourced manufacturing facilities. Rising demand for specialty therapeutics and complex biologics further accelerated long-term partnerships between pharmaceutical innovators and CDMO providers.

Restraining Factor

Strict regulatory compliance and quality management requirements.

The CDMO market faces significant operational challenges because of stringent global regulatory standards and complex quality assurance requirements. Approximately 43% of manufacturing facilities reported increased compliance expenditures during 2025 due to evolving pharmaceutical regulations. Multi-site inspection delays affected nearly 26% of outsourced drug manufacturing projects globally. Around 37% of pharmaceutical clients demanded advanced serialization and traceability systems within manufacturing operations. Quality control failures accounted for approximately 18% of delayed commercial production approvals during 2024. Workforce shortages in regulatory affairs and validation engineering impacted nearly 22% of CDMO operational expansion projects. Compliance modernization costs for biologics manufacturing facilities also increased by approximately 19% across major pharmaceutical outsourcing hubs.

Expansion of biologics and cell therapy manufacturing services.

Opportunity

The increasing commercialization of biologics, biosimilars, and advanced therapies creates strong opportunities for Contract Development and Manufacturing Organizations (CDMOs). Approximately 58% of biotechnology companies outsourced monoclonal antibody manufacturing during 2025. Cell and gene therapy manufacturing partnerships increased by 31% globally during 2024. Single-use manufacturing technologies represented nearly 36% of new biologics facility investments. Around 47% of pharmaceutical innovators prioritized flexible manufacturing capabilities for personalized medicine production. AI-integrated process optimization systems improved biologics manufacturing efficiency by approximately 21%.

Capacity limitations and supply chain disruptions.

Challenge

Capacity constraints and raw material supply disruptions remain major challenges affecting the CDMO market globally. Approximately 39% of pharmaceutical outsourcing projects experienced manufacturing delays during 2024 because of limited production capacity and material shortages. Biologics manufacturing utilization rates exceeded 78% across major CDMO facilities during 2025. Around 34% of companies faced procurement difficulties for specialized pharmaceutical ingredients and single-use systems. Transportation and logistics disruptions increased operational lead times by approximately 17% globally. Workforce shortages in bioprocess engineering and pharmaceutical manufacturing affected nearly 24% of facility expansion plans.

• Download Free Sample to learn more about this report

•  

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET REGIONAL INSIGHTS

• North America

North America accounted for approximately 39% of the Contract Development and Manufacturing Organizations (CDMOs) market during 2025 because of advanced pharmaceutical research infrastructure and strong biologics manufacturing capacity. The United States represented nearly 84% of regional outsourcing demand due to increasing monoclonal antibody production and clinical manufacturing projects. Around 63% of pharmaceutical companies in North America outsourced at least one manufacturing operation during 2025. Sterile injectable manufacturing represented approximately 36% of regional CDMO service demand globally. Cell and gene therapy outsourcing projects increased by 29% during 2024 because of rising advanced therapy clinical trials. AI-integrated manufacturing analytics improved production efficiency by approximately 24% across large biologics facilities.

Continuous manufacturing technologies expanded by 21% across oral solid dosage production plants. Around 48% of regional CDMOs integrated cloud-connected quality management systems for real-time compliance monitoring and operational optimization. Biologics manufacturing utilization rates exceeded 79% across major North American outsourcing facilities during 2025. Single-use bioreactor installations increased by approximately 26% due to flexible small-batch production requirements. Clinical packaging and serialization projects also expanded by 18% globally because of increasing pharmaceutical regulatory requirements and specialty therapeutic commercialization activities.

• Europe

Europe represented approximately 28% of the Contract Development and Manufacturing Organizations (CDMOs) market because of strong pharmaceutical regulations, advanced manufacturing infrastructure, and rising biologics outsourcing activity. Germany, Switzerland, and the United Kingdom collectively contributed nearly 61% of regional CDMO demand during 2025. Biologics manufacturing represented approximately 39% of outsourcing activity globally. Sterile injectable manufacturing projects increased by 24% across European pharmaceutical facilities during 2024. Around 53% of pharmaceutical innovators in Europe outsourced formulation development and commercial manufacturing operations. Continuous manufacturing systems improved production throughput by approximately 20% across large-scale manufacturing facilities.

Single-use production technologies represented nearly 31% of biologics manufacturing investments during 2025. High-potency API production capacity also increased by 17% because of rising oncology drug development demand. Europe experienced increasing investments in sustainable pharmaceutical manufacturing and energy-efficient processing systems. Approximately 28% of regional CDMOs implemented waste reduction and carbon optimization technologies during 2025. AI-enabled quality monitoring systems improved compliance efficiency by nearly 19% across outsourced pharmaceutical operations. Personalized medicine manufacturing and specialty drug packaging projects also increased significantly across the region.

• Asia-Pacific

Asia-Pacific accounted for approximately 25% of the Contract Development and Manufacturing Organizations (CDMOs) market during 2025 because of cost-efficient pharmaceutical manufacturing and rapid biotechnology expansion. China, India, Japan, and South Korea collectively represented nearly 69% of regional outsourcing activity. API development projects accounted for approximately 42% of regional CDMO demand because of large-scale generic drug manufacturing operations. Around 58% of pharmaceutical outsourcing projects in Asia-Pacific involved oral solid dosage production during 2025. Biologics manufacturing investments increased by 27% during 2024 because of expanding monoclonal antibody and biosimilar production capabilities. Single-use bioreactor adoption improved manufacturing flexibility by approximately 22% across regional facilities. Around 44% of biotechnology startups partnered with CDMOs for early-stage process development and regulatory support services.

AI-enabled production monitoring systems also increased by 18% globally. India experienced strong growth in API manufacturing and vaccine production outsourcing due to rising pharmaceutical exports. China expanded high-potency API and biologics manufacturing capacity by approximately 24% during 2025. Japan and South Korea focused heavily on cell therapy production and advanced drug delivery technologies supporting precision medicine commercialization projects across the region.

• Middle East & Africa

Middle East & Africa represented approximately 8% of the Contract Development and Manufacturing Organizations (CDMOs) market because of expanding pharmaceutical production infrastructure and increasing regional healthcare investments. Saudi Arabia, the United Arab Emirates, and South Africa collectively contributed nearly 54% of regional outsourcing demand during 2025. Secondary packaging and oral dosage manufacturing represented approximately 43% of CDMO activity across the region. Around 37% of pharmaceutical companies outsourced packaging and labeling services to regional manufacturing partners. Biologics manufacturing investments increased by 16% during 2024 because of growing demand for specialty therapeutics and imported pharmaceutical alternatives. Continuous manufacturing technologies improved production efficiency by approximately 18% across regional pharmaceutical plants.

Generic drug outsourcing projects represented nearly 31% of CDMO demand globally. Workforce training and regulatory modernization initiatives also expanded across major pharmaceutical manufacturing hubs. Africa experienced increasing pharmaceutical outsourcing for vaccine filling, packaging, and API production due to rising healthcare access initiatives. Approximately 21% of regional CDMO projects involved sterile injectable manufacturing during 2025. Cloud-connected quality monitoring systems improved compliance efficiency by nearly 15% across pharmaceutical production facilities. Regional governments also expanded investments in domestic pharmaceutical manufacturing infrastructure and supply chain localization projects.

LIST OF TOP CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) COMPANIES

• Lonza
• Catalent
• Patheon (Thermo Fisher Scientific)
• Aenova
• Siegfried
• Recipharm
• Strides Shasun
• Piramal
• Metrics
• AMRI
• Famar
• WuXi AppTech
• Asymchem
• Porton
• Amatsigroup

Top 2 Companies With Highest Market Share

• Lonza: Accounted for approximately 17% of global CDMO market share due to strong biologics and cell therapy manufacturing capabilities.
• Catalent: Held nearly 14% market share supported by extensive pharmaceutical manufacturing and drug delivery service operations.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Contract Development and Manufacturing Organizations (CDMOs) market continues attracting substantial investments due to rising pharmaceutical outsourcing, biologics commercialization, and advanced therapy manufacturing expansion. Approximately 63% of pharmaceutical companies increased outsourcing investments during 2025 to improve operational flexibility and reduce infrastructure costs. Biologics manufacturing projects represented nearly 39% of total CDMO investment activity globally. Single-use bioprocessing technologies increased by 26% across newly established manufacturing facilities during 2024. Cell and gene therapy manufacturing attracted approximately 31% higher investment allocation because of growing clinical trial activity and precision medicine demand. AI-enabled production analytics systems improved operational efficiency by nearly 22% across pharmaceutical outsourcing facilities.

High-potency API production capacity also expanded by 19% globally because of increasing oncology drug development projects. Asia-Pacific recorded approximately 27% growth in pharmaceutical manufacturing infrastructure investments during 2025. Flexible manufacturing systems supporting small-batch personalized medicine production gained strong investor interest globally. Around 44% of biotechnology startups partnered with CDMOs for scalable manufacturing support and regulatory expertise. Sustainable pharmaceutical manufacturing technologies, including energy-efficient processing and waste reduction systems, increased by nearly 18% across modern outsourcing facilities. Automation-enabled packaging and cloud-connected quality management systems also created significant long-term investment opportunities within global pharmaceutical outsourcing networks.

NEW PRODUCT DEVELOPMENT

New product development within the Contract Development and Manufacturing Organizations (CDMOs) market increasingly focuses on biologics manufacturing, advanced drug delivery systems, and AI-enabled production technologies. Approximately 42% of newly launched CDMO platforms during 2025 included AI-assisted quality monitoring and predictive manufacturing analytics. Single-use bioreactor systems represented nearly 34% of biologics facility innovation projects globally. Cell and gene therapy manufacturing technologies expanded by approximately 28% during 2024 because of increasing precision medicine commercialization. Advanced sterile injectable manufacturing systems improved contamination control efficiency by nearly 23% across pharmaceutical outsourcing facilities. High-potency API manufacturing technologies also increased by 19% globally due to rising specialty oncology therapeutic production.

Around 47% of CDMOs integrated cloud-based manufacturing execution systems for real-time process monitoring and regulatory compliance management during 2025. Drug delivery innovation remained a major focus area, with liposomal formulations and nanoparticle-based delivery technologies increasing by approximately 17% globally. Continuous manufacturing systems improved production scalability by nearly 20% across oral solid dosage facilities. Automated packaging technologies supporting serialization and traceability also expanded significantly. Sustainable manufacturing equipment utilizing low-energy processing systems represented approximately 16% of new pharmaceutical manufacturing technology deployments worldwide.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, Lonza expanded biologics manufacturing capacity with new single-use bioreactor systems supporting large-scale monoclonal antibody production.
• During 2024, Catalent introduced AI-enabled pharmaceutical manufacturing analytics improving batch monitoring efficiency by approximately 22%.
• In 2023, WuXi AppTech increased high-potency API production capacity by nearly 18% to support oncology drug outsourcing demand.
• During 2025, Patheon (Thermo Fisher Scientific) launched advanced sterile injectable manufacturing systems supporting personalized medicine production projects.
• In 2024, Recipharm integrated cloud-connected quality management systems improving compliance monitoring across multi-site pharmaceutical operations.

REPORT COVERAGE OF CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) MARKET

The Contract Development and Manufacturing Organizations (CDMOs) market report provides comprehensive analysis of pharmaceutical outsourcing trends, biologics manufacturing expansion, advanced therapy production, and regulatory compliance developments across global healthcare industries. The report evaluates more than 15 major CDMO companies and analyzes over 50 service categories including API development, biologics manufacturing, sterile injectables, packaging, drug delivery systems, and clinical trial support operations. Manufacturing services represented approximately 46% of analyzed market demand globally during 2025. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, assessing pharmaceutical outsourcing infrastructure, biotechnology investments, regulatory modernization, and manufacturing capacity utilization trends.

Approximately 39% of report analysis focuses on North America due to extensive biologics outsourcing and pharmaceutical innovation activities. Asia-Pacific accounted for nearly 25% of report coverage because of expanding API manufacturing and generic drug production capabilities. The report also evaluates technological innovations including AI-enabled production analytics, cloud-connected manufacturing execution systems, continuous manufacturing technologies, and single-use bioprocessing platforms. Biologics manufacturing represented approximately 38% of analyzed outsourcing activity globally during 2025. Operational efficiency metrics, regulatory compliance trends, serialization requirements, sustainability initiatives, and supply chain optimization strategies are extensively assessed throughout the report coverage across pharmaceutical and biotechnology outsourcing operations worldwide.